Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous Leukemia

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Rosen, David B ^c   Putta, Santosh ^c   Covey, Todd ^c   Huang, Ying Wen ^c   Nolan, Garry P ^b   Cesano, Alessandra ^c   Minden, Mark D ^a   Fantl, Wendy J ^b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Nodality Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ETOPOSIDE; JANUS KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; STAT PROTEIN; STAUROSPORINE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL SUBPOPULATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DISEASE MARKER; DNA DAMAGE; DNA REPAIR; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; DRUG EFFECT; GENETICS; INTRACELLULAR SPACE; METABOLISM; PATHOLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; DNA DAMAGE; ETOPOSIDE; HUMANS; INTRACELLULAR SPACE; JANUS KINASES; LEUKEMIA, MYELOID, ACUTE; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; STAUROSPORINE;

EID: 77957859817     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012405     Document Type: Article

References (68)

1. Pawson T, Linding R (2008) Network medicine. FEBS Lett 582: 1266-1270.
2. Cox J, Mann M (2007) Is proteomics the new genomics? Cell 130: 395-398.
3. Irish JM, Kotecha N, Nolan GP (2006) Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nat Rev Cancer 6: 146-155.
4. Danna EA, Nolan GP (2006) Transcending the biomarker mindset: deciphering disease mechanisms at the single cell level. Curr Opin Chem Biol 10: 20-27.
5. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, et al. (2004) Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118: 217-228.
6. Irish JM, Czerwinski DK, Nolan GP, Levy R (2006) Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumorinfiltrating nonmalignant B cells. Blood 108: 3135-3142.
7. Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, et al. (2008) Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 14: 335-343.
8. Fraser ID, Germain RN (2009) Navigating the network: signaling cross-talk in hematopoietic cells. Nat Immunol 10: 327-331.
9. Shipley JL, Butera JN (2009) Acute myelogenous leukemia. Exp Hematol 37: 649-658.
10. Estey E, Dohner H (2006) Acute myeloid leukaemia. Lancet 368: 1894-1907.
11. Mrozek K, Radmacher MD, Bloomfield CD, Marcucci G (2009) Molecular signatures in acute myeloid leukemia. Curr Opin Hematol 16: 64-69.
12. Schlenk RF, Dohner K (2009) Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. Curr Opin Hematol 16: 98-104.
13. Marcucci G (2009) Molecular markers in acute myeloid leukemia. Clin Adv Hematol Oncol 7: 448-451.
14. Lowenberg B (2008) Acute myeloid leukemia: the challenge of capturing disease variety. Hematology Am Soc Hematol Educ Program. pp 1-11.
15. Baldus CD, Mrozek K, Marcucci G, Bloomfield CD (2007) Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review. Br J Haematol 137: 387-400.
16. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrozek K, et al. (2010) Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated geneand microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 28: 596-604.
17. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, et al. (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361: 1058-1066.
18. Lowenberg B, Downing JR, Burnett A (1999) Acute myeloid leukemia. N Engl J Med 341: 1051-1062.
19. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, et al. (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358: 1909-1918
20. Ravandi F, Burnett AK, Agura ED, Kantarjian HM (2007) Progress in the treatment of acute myeloid leukemia. Cancer 110: 1900-1910.
21. Tallman MS, Gilliland DG, Rowe JM (2005) Drug therapy for acute myeloid leukemia. Blood 106: 1154-1163.
22. Coffer PJ, Koenderman L, de Groot RP (2000) The role of STATs in myeloid differentiation and leukemia. Oncogene 19: 2511-2522.
23. Bromberg J, Darnell JE, Jr. (2000) The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19: 2468-2473.
24. Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497-5510.
25. Vogt PK, Gymnopoulos M, Hart JR (2009) PI 3-kinase and cancer: changing accents. Curr Opin Genet Dev 19: 12-17.
26. Brierley MM, Fish EN (2005) Stats: multifaceted regulators of transcription. J Interferon Cytokine Res 25: 733-744.
27. Basham B, Sathe M, Grein J, McClanahan T, D'Andrea A, et al. (2008) In vivoidentification of novel STAT5 target genes. Nucleic Acids Res 36: 3802-3818.
28. Kornblau SM, Minden MD, Rosen DB, Putta S, Cohen A, et al. (2010) Dynamic single cell network profiles in AML are associated with patient response to standard induction therapy. Clin Cancer Res:In press.
29. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70.
30. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, et al. (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115: 453-474.
31. Krutzik PO, Nolan GP (2003) Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 55: 61-70.
32. Irish JM, Czerwinski DK, Nolan GP, Levy R (2006) Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J Immunol 177: 1581-1589.
33. Stelzer GT, Shults KE, Loken MR (1993) CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann N Y Acad Sci 677: 265-280.
34. Jolliffe IT (2002) Principal Component Analysis. Springer, NY. 487 p.
35. Bromberg J (2002) Stat proteins and oncogenesis. J Clin Invest 109: 1139-1142.
36. Valentino L, Pierre J (2006) JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 71: 713-721.
37. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, et al. (2009) Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 18: 1333-1349.
38. Kok K, Nock GE, Verrall EA, Mitchell MP, Hommes DW, et al. (2009) Regulation of p110delta PI 3-kinase gene expression. PLoS ONE 4: e5145.
39. Kishimoto T (2006) Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 8(Suppl 2): S2.
40. Seita J, Asakawa M, Ooehara J, Takayanagi S, Morita Y, et al. (2008) Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood 111: 1903-1912.
41. Yoshida H, Nakaya M, Miyazaki Y (2009) Interleukin 27: a double-edged sword for offense and defense. J Leukoc Biol 86: 1295-1303.
42. Kok K, Geering B, Vanhaesebroeck B (2009) Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci 34: 115-127.
43. Meyuhas O (2008) Physiological roles of ribosomal protein S6: one of its kind. Int Rev Cell Mol Biol 268: 1-37.
44. Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, et al. (2007) RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 282: 14056-14064.
45. Antoni L, Sodha N, Collins I, Garrett MD (2007) CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? Nat Rev Cancer 7: 925-936
46. Harper JW, Elledge SJ (2007) The DNA damage response: ten years after. Mol Cell 28: 739-745.
47. Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature 461: 1071-1078.
48. Dai Y, Grant S (2010) New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 16: 376-383.
49. Muslimovic A, Nystrom S, Gao Y, Hammarsten O (2009) Numerical analysis of etoposide induced DNA breaks. PLoS ONE 4: e5859.
50. Couldwell WT, Hinton DR, He S, Chen TC, Sebat I, et al. (1994) Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett 345: 43-46.
51. Benekli M, Xia Z, Donohue KA, Ford LA, Pixley LA, et al. (2002) Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 99: 252-257.
52. Benekli M, Baer MR, Baumann H, Wetzler M (2003) Signal transducer and activator of transcription proteins in leukemias. Blood 101: 2940-2954.
53. Baker SJ, Rane SG, Reddy EP (2007) Hematopoietic cytokine receptor signaling. Oncogene 26: 6724-6737.
54. Bunting KD (2007) STAT5 signaling in normal and pathologic hematopoiesis. Front Biosci 12: 2807-2820.
55. Han L, Wierenga AT, Rozenveld-Geugien M, van de Lande K, Vellenga E, et al. (2009) Single-cell STAT5 signal transduction profiling in normal and leukemic stem and progenitor cell populations reveals highly distinct cytokine responses. PLoS ONE 4: e7989.
56. Wierenga AT, Vellenga E, Schuringa JJ (2008) Maximal STAT5-induced proliferation and self-renewal at intermediate STAT5 activity levels. Mol Cell Biol 28: 6668-6680.
57. Kim HS, Lee MS (2007) STAT1 as a key modulator of cell death. Cell Signal 19: 454-465.
58. Cheong JW, Eom JI, Maeng HY, Lee ST, Hahn JS, et al. (2003) Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome. Br J Haematol 122: 454-456.
59. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, et al. (2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441: 475-482.
60. Choudhary C, Muller-Tidow C, Berdel WE, Serve H (2005) Signal transduction of oncogenic Flt3. Int J Hematol 82: 93-99.
61. Sujobert P, Bardet V, Cornillet-Lefebvre P, Hayflick JS, Prie N, et al. (2005) Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106: 1063-1066.
62. Masson K, Ronnstrand L (2009) Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Cell Signal 21: 1717-1726.
63. Meshinchi S, Appelbaum FR (2009) Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res 15: 4263-4269.
64. de Jonge-Peeters SD, Kuipers F, de Vries EG, Vellenga E (2007) ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol 62: 214-226.
65. Ho MM, Hogge DE, Ling V (2008) MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. Exp Hematol 36: 433-442.
66. Svirnovski AI, Shman TV, Serhiyenka TF, Savitski VP, Smolnikova VV, et al. (2009) ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells. Hematology 14: 204-212.
67. Doepfner KT, Boller D, Arcaro A (2007) Targeting receptor tyrosine kinase signaling in acute myeloid leukemia. Crit Rev Oncol Hematol 63: 215-230.
68. Fathi AT, Grant S, Karp JE (2010) Exploiting cellular pathways to develop new treatment strategies for AML. Cancer Treat Rev 36: 142-150.